I have covered Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) twice before, and on both occasions, my predictions of share price performance on the basis of fundamental analysis were proved correct over the following months. MyI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the ke ...

交易概述 - 伯克希尔哈撒韦接近以约100亿美元收购西方石油公司旗下化工业务OxyChem [1] - 该交易可能在未来几天内最终确定 若完成将是公司自2022年以116亿美元收购保险公司Alleghany以来最大的一笔交易 [2] - 公司目前持有创纪录的3440亿美元现金储备 [2] 公司背景与关联 - 伯克希尔哈撒韦已持有超过110亿美元西方石油公司股票 持股比例达28.2% [4] - 公司曾在2019年出资100亿美元支持西方石油公司收购阿纳达科石油公司 并因此获得优先股和认股权证 [4] - 亿万富翁投资者于2022年初开始在公开市场买入西方石油公司普通股 利用了新冠疫情带来的市场波动以折扣价买入 [5] 领导层与市场反应 - 巴菲特将于2025年底卸任伯克希尔哈撒韦CEO 但保留董事长职务 其继任者Greg Abel在能源行业拥有深厚专业知识 [3] - 尽管有收购报道 西方石油公司股价在周二下跌了1.8% [3] 被收购方业务 - 西方石油公司提供2%的股息收益率 并且一直在投资碳捕获业务 [5]

Spirit Airlines has negotiated funding of up to $475 million with existing bondholders to support normal business operations during its Chapter 11 restructuring, its parent company said on Tuesday. ...

Earlier on August 19, Erik Woodring of Morgan Stanley joined CNBC’s ‘The Exchange’ to discuss the most under-owned tech stocks and what’s behind the bifurcation in the sector. Woodring believes that mega-cap tech is under-owned in the market, as Morgan Stanley revealed that these stocks are the most under-owned by actively managed funds in over 16 years. The gap between the portfolio weightings of these stocks and their weightings in the S&P 500 index widened significantly in the second quarter. Despite thi ...

TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at htt ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert into bone. According to the OPTIMA trial, at 56 weeks, both garetosmab dosages decreased new bone lesion ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the "Baird Chautauqua International and Global Growth Fund". A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching new highs. Markets fell following the President's announcement of unexpectedly severe tariffs, which raised recession fears. After a bri ...

Evkeeza标签扩展获批 - 美国FDA批准Evkeeza标签扩展 用于治疗1至5岁以下纯合子家族性高胆固醇血症儿童患者 作为饮食控制和其他降脂疗法的辅助治疗[1] - 此次标签扩展基于六名HoFH患儿的临床疗效和安全性数据支持 其中四名患者提供了药代动力学数据[2] - Evkeeza最初于2021年获批用于12岁及以上HoFH患者 随后扩展至5至11岁儿童群体[2] Evkeeza商业表现与合作 - 2025年上半年Evkeeza在美国市场销售额达7210万美元[3] - Regeneron负责Evkeeza在美国的开发和分销 Ultragenyx负责美国以外地区的临床开发、商业化和分销[4] - 公司另一款药物Praluent同样获批用于HoFH适应症[4] Eylea销售压力与应对措施 - 主力产品Eylea销售额近年承压 主要面临罗氏Vabysmo的竞争压力[5] - Eylea是公司营收的最大贡献者 其销售额快速下滑对公司整体营收产生负面影响[6] - 为应对Eylea销售下滑 公司开发了高剂量版本Eylea HD 其第二季度美国销售额因需求增长推动销量上升而增长29%[9] 产品组合多元化进展 - 公司与赛诺菲合作的Dupixent销售额表现强劲 该药物已获批用于特应性皮炎、哮喘等多项适应症[10] - 肿瘤产品管线取得进展 Libtayo表现良好 其在皮肤鳞状细胞癌辅助治疗中的潜在标签扩展有望推动增长[11] - 近期获批的Lynozyfic用于治疗复发或难治性多发性骨髓瘤 进一步增强了公司产品组合[11] 公司股价表现 - 公司股价年内下跌20.5% 同期行业指数上涨3.9%[6]

About two and a half months have passed since my last article , "Regeneron Pharmaceuticals: My Highest Conviction Pharmaceutical Pick for 2025," and during that time, its stock price has risen by 2.5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical compan ...

About two and a half months have passed since my last article , "Regeneron Pharmaceuticals: My Highest Conviction Pharmaceutical Pick for 2025," and during that time, its stock price has risen by 2.5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical compan ...